TY  - JOUR
A1  - Geiger, Nina
A1  - König, Eva-Maria
A1  - Oberwinkler, Heike
A1  - Roll, Valeria
A1  - Diesendorf, Viktoria
A1  - Fähr, Sofie
A1  - Obernolte, Helena
A1  - Sewald, Katherina
A1  - Wronski, Sabine
A1  - Steinke, Maria
A1  - Bodem, Jochen
T1  - Acetylsalicylic acid and salicylic acid inhibit SARS-CoV-2 replication in precision-cut lung slices
JF  - Vaccines
N2  - Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.
KW  - acetylsalicylic acid
KW  - salicylic acid
KW  - antiviral activity
KW  - aspirin
KW  - SARS-CoV-2
KW  - precision-cut lung slices
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-289885
SN  - 2076-393X
VL  - 10
IS  - 10
ER  -